KCG Holdings Inc. bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the first quarter, Holdings Channel reports. The fund bought 30,407 shares of the biopharmaceutical company’s stock, valued at approximately $122,000.
Separately, Renaissance Technologies LLC boosted its position in Xenon Pharmaceuticals by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 114,200 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 18,000 shares in the last quarter. Institutional investors own 56.01% of the company’s stock.
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) traded up 5.45% during midday trading on Thursday, hitting $2.90. 10,057 shares of the stock traded hands. The firm’s market capitalization is $52.19 million. The company’s 50-day moving average is $3.30 and its 200 day moving average is $5.14. Xenon Pharmaceuticals Inc. has a 52 week low of $2.70 and a 52 week high of $9.95.
Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.03. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.38 million. Xenon Pharmaceuticals had a negative net margin of 3,489.63% and a negative return on equity of 47.53%. Analysts anticipate that Xenon Pharmaceuticals Inc. will post ($0.96) earnings per share for the current year.
XENE has been the topic of several recent analyst reports. Zacks Investment Research cut shares of Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Canaccord Genuity reissued a “buy” rating and set a $5.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 27th. Finally, Jefferies Group LLC set a $5.00 target price on shares of Xenon Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $11.88.
In related news, insider Value Fund L. P. Biotechnology acquired 20,411 shares of the stock in a transaction that occurred on Thursday, June 22nd. The shares were bought at an average price of $4.00 per share, for a total transaction of $81,644.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Value Fund L. P. Biotechnology acquired 26,408 shares of the stock in a transaction that occurred on Monday, June 19th. The shares were bought at an average price of $3.84 per share, for a total transaction of $101,406.72. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 490,978 shares of company stock worth $1,891,534. 9.40% of the stock is owned by insiders.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
